{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:32:16Z","timestamp":1791415936017,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"am","delay-in-days":303,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO-2011\/03\/N\/NZ6\/00059"],"award-info":[{"award-number":["UMO-2011\/03\/N\/NZ6\/00059"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"National Centre for Research and Development","doi-asserted-by":"publisher","award":["LIDER\/1\/0031\/L-7\/15\/NCBR\/2016"],"award-info":[{"award-number":["LIDER\/1\/0031\/L-7\/15\/NCBR\/2016"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.bmc.2022.116858","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:30:52Z","timestamp":1653816652000},"page":"116858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Anti-HCV and Zika activities of ribavirin C-nucleosides analogues"],"prefix":"10.1016","volume":"68","author":[{"given":"Simon","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Brzuska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Ouarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Gallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Solarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang\u00e9lique","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Uziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Lubin-Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2022.116858_b0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2022.116858_b0010","unstructured":"Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01056523."},{"key":"10.1016\/j.bmc.2022.116858_b0015","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.3109\/10428194.2010.496506","article-title":"Ribavirin as an anti-cancer therapy: acute mueloid leukemia and beyond?","volume":"51","author":"Borden","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bmc.2022.116858_b0020","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1182\/blood.V124.21.5278.5278","article-title":"The anti-leukemia role and mechanism of ribavirin in Ph+ leukemia","volume":"124","author":"Gong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2022.116858_b0025","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/1535-7163.MCT-18-0666","article-title":"The use of ribavirin as an anticancer therapeutic: will it go viral?","volume":"18","author":"Casaos","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2022.116858_b0030","unstructured":"Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=Ribavirin+(RBV)&page=1."},{"key":"10.1016\/j.bmc.2022.116858_b0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1021\/acscentsci.0c00272","article-title":"Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases","volume":"6","author":"Liu","year":"2020","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.bmc.2022.116858_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225860","article-title":"Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells","volume":"14","author":"Wambecke","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2022.116858_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112009","article-title":"Synthesis and antitumor activities investigation of a C-nucleoside analogue of Ribavirin","volume":"188","author":"Sabat","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2022.116858_b0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","article-title":"Ribavirin: a drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance","volume":"8","author":"Beaucourt","year":"2014","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bmc.2022.116858_b0055","doi-asserted-by":"crossref","unstructured":"a) Pardo J, Shukla AM, Chamarthi G, Gupte A. Drugs in context 2020;9:1. b) Reza Hashemian SM, Farhadi T, Velayati AA. Drug design. Dev Ther 2020;14:3215.","DOI":"10.7573\/dic.2020-4-14"},{"key":"10.1016\/j.bmc.2022.116858_b0060","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1021\/acs.jmedchem.5b01157","article-title":"C-Nucleosides to be revised","volume":"59","author":"De Clercq","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2022.116858_b0065","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/138955711793564051","article-title":"Recent advances and future perspectives of triazole analogs as promising antiviral agents","volume":"11","author":"Kharb","year":"2011","journal-title":"Mini-Rev Med Chem"},{"key":"10.1016\/j.bmc.2022.116858_b0070","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1039\/D1OB02451E","article-title":"Synthesis of novel C-nucleoside analogues bearing an anomeric cyano and a 1,2,3-triazole nucleobase as potential antiviral agents","volume":"20","author":"Sierocki","year":"2022","journal-title":"Org Biomol Chem"},{"key":"10.1016\/j.bmc.2022.116858_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117592","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2022.116858_b0080","doi-asserted-by":"crossref","first-page":"17006","DOI":"10.1038\/nrdp.2017.6","article-title":"Hepatitis C virus infection","volume":"3","author":"Manns","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmc.2022.116858_b0085","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.3389\/fmicb.2018.03252","article-title":"Zika virus: origins, pathological action, and treatment strategies","volume":"9","author":"Gorshkov","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.bmc.2022.116858_b0090","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1055\/s-0036-1588409","article-title":"Synthesis of C-ribosyl-1,2,3-triazolyl carboxamides","volume":"49","author":"Solarte","year":"2017","journal-title":"Synthesis"},{"key":"10.1016\/j.bmc.2022.116858_b0095","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3762\/bjoc.13.74","article-title":"Synthesis of ribavirin 2\u2019-Me-C-nucleosides analogues","volume":"13","author":"Cosson","year":"2017","journal-title":"Beilstein J Org Chem"},{"key":"10.1016\/j.bmc.2022.116858_b0100","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1021\/jo900594x","article-title":"Huisgen cycloaddition reaction of C-alkynyl ribosides under micellar catalysis: synthesis of ribavirin analogues","volume":"74","author":"Ait Youcef","year":"2009","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2022.116858_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105723","article-title":"Synthesis, antiviral and antitumor activities investigations of a series of Ribavirin C-nucleoside analogue prodrugs","volume":"122","author":"Sabat","year":"2022","journal-title":"Bioorganic Chem"},{"key":"10.1016\/j.bmc.2022.116858_b0110","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1128\/AAC.44.5.1276-1283.2000","article-title":"The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels","volume":"4","author":"Tam","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2022.116858_b0115","unstructured":"Weis AL, Shanmuganathan K, Goodhue CT, l-ribofuranosyl nucleosides, EP1132393A1, US5559101A."},{"key":"10.1016\/j.bmc.2022.116858_b0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1128\/AAC.24.1.134","article-title":"Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin","volume":"24","author":"Koff","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2022.116858_b0125","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3390\/molecules22111869","article-title":"Biophysical properties and antiviral activities of meales fusion protein drived peptide conjugated with 25-hydroxycholesterol","volume":"22","author":"Gomes","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2022.116858_b0130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bbamem.2018.10.011","article-title":"Studies of membranotropic and fusogenic activity of two putative HCV fusion peptides","volume":"1861","author":"Gonzalez","year":"2019","journal-title":"BBA Biomembranes"},{"key":"10.1016\/j.bmc.2022.116858_b0135","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1021\/acs.accounts.7b00455","article-title":"Membrane crossing and membranotropic activity of cell-penetrating peptides: dangerous liaisons?","volume":"50","author":"Walrant","year":"2017","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmc.2022.116858_b0140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.antiviral.2009.04.007","article-title":"A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication","volume":"83","author":"Iro","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2022.116858_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.08.007","article-title":"Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice","volume":"146","author":"Kamiyama","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2022.116858_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.antiviral.2017.09.004","article-title":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus","volume":"146","author":"Mumtaz","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bmc.2022.116858_b0155","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1038\/s41598-021-87707-9","article-title":"The antiviral effect of metformin on zika and dengue virus infection","volume":"11","author":"Farfan-Morales","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2022.116858_b0160","doi-asserted-by":"crossref","unstructured":"Khiali S, khani E, Rouy S.B. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic. Future Microbiol 2022;17:377\u201391.","DOI":"10.2217\/fmb-2021-0252"},{"key":"10.1016\/j.bmc.2022.116858_b0165","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3390\/molecules23071547","article-title":"Szewczyk B Anti-hepatitis C virus activity of uridine derivatives of 2-deoxy sugars","volume":"23","author":"Krol","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2022.116858_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040206618807580","article-title":"The effectiveness of antiviral agents with broad-spectrum activity against chikungunya virus varies between host cell lines","volume":"26","author":"Franco","year":"2018","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.bmc.2022.116858_b0175","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/nano6080141","article-title":"Galactosylated liposomes for targeted co-delivery of doxorubicin\/vimentin siRNA to hepatocellular carcinoma","volume":"6","author":"Oh","year":"2016","journal-title":"Nanomaterials"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622002504?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089622002504?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:18:31Z","timestamp":1760836711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089622002504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":35,"alternative-id":["S0968089622002504"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116858","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-HCV and Zika activities of ribavirin C-nucleosides analogues","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2022.116858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116858"}}